MAPT and Alzheimer disease: The gold standard methods for obtaining in vivo biomarkers of AD are either the analysis of cerebrospinal fluid (CSF) or positron emission tomography (PET) imaging of amyloid beta (Aβ) and neurofibrillary tangle tau.